hepatitis C
FDA approves first two antiviral hep C drugs for paediatric patients
April 10, 2017Sales and Marketing FDA, harvoni, hepatitis C, sovaldi
The FDA has given the go-ahead for two hepatitis C treatments for use in young and adolescent patients: Sovaldi (sofosbuvir) …
Hepatitis C market set for slump as cure rates rise
February 14, 2017Manufacturing and Production, Medical Communications, Sales and Marketing Gilead, hepatitis C
Objectively, it is the pharmaceutical industries intention to find cures for diseases and to aid patients to live a full …
EMA Accelerated Assessment for AbbVie’s hepatitis C regimen
January 24, 2017Manufacturing and Production, Research and Development AbbVie, EMA, hepatitis C
AbbVie has announced that its investigational, pan-genotypic regimen of Glecaprevir/Pibrentasvir has been awarded Accelerated Assessment by the European Medicines Agency …
AbbVie investigational hep C drug boasts 97.5% response rate
November 15, 2016Manufacturing and Production, Medical Communications, Research and Development AbbVie, hepatitis C, pan-genotypic
AbbVie released details on their latest trials for their investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530). In an eight week …
FDA warns that certain hepatitis C drugs can have serious side-effects
October 5, 2016Medical Communications, Research and Development FDA, hepatitis B, hepatitis C
The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …
Provisional NICE recommendation for Gilead’s Hepatitis C treatment
September 28, 2016Research and Development, Sales and Marketing Epclusa, NICE, hepatitis C
NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment …
AbbVie scores EU recommendation for shorter treatment of Viekirax in hepatitis C
July 25, 2016Research and Development, Sales and Marketing EU, Gilead, Viekirax, hepatitis C
AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic …
FDA approves Gilead’s Harvoni in two new indications
February 18, 2016Research and Development Gilead Sciences, MSD, harvoni, hepatitis C
The hepatitis C treatment battle had its latest development yesterday, with the FDA awarding Gilead Science’s market-leading drug Harvoni (ledipasvir/sofosbuvir) …
MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst
February 10, 2016Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C
The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …
MSD gets FDA approval for hepatitis C drug Zepatier
January 29, 2016Medical Communications, Sales and Marketing FDA, MSD, Zepatier, hepatitis C
The competitive hepatitis C market is to get another contender, with FDA approving MSD’s new combo treatment Zepatier (elbasvir and …
AbbVie tests new hepatitis C drug in Phase III trials
January 11, 2016Research and Development AbbVie, clinical trials, hepatitis C, phase III
AbbVie has announced it has begun six global Phase III trials of its once-daily, ribavirin-free investigational hepatitis C virus regimen, …
Gilead’s Sovaldi wins Drug Discovery of the Year Award
December 16, 2015Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi
Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …
Gilead awaits EU decision on hep C combo treatment
December 8, 2015Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir
The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …
BMS and Medicines Patent Pool collaborate to increase Hep C medicine access
November 25, 2015Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C
The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …
Medicines Patent Pool to include hep C and TB drugs
November 9, 2015Sales and Marketing Medicines Patent Pool, affordable drugs, hep C, hepatitis, hepatitis C, medicines access, tuberculosis
The Medicines Patent Pool has expanded to include a mandate to make treatments for hepatitis C and tuberculosis affordable and …
Latest content
FibroFind appoints Lee Borthwick as CEO
